Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

NCT02436707 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

129

Enrollment

NETWORK

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Ibrutinib
DRUG: Rituximab
DRUG: Gemcitabine
DRUG: Dexamethasone
DRUG: Cisplatin
DRUG: Mesna
DRUG: Cyclophosphamide
DRUG: Etoposide
DRUG: G-CSF
DRUG: Selinexor

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]
[object Object]
[object Object]